6-K filed Jul 30, 2026 at 07:18 ET
HUTCHMED reported H1 2026 results with total revenue essentially flat at $278.3M (vs $277.7M in H1 2025) but a strong 23% increase in Oncology/Immunology marketed product revenue to $121.4M, driven by ELUNATE (+41%), SULANDA (+45%), and FRUZAQLA ex-US (+70%). Net income attributable to HUTCHMED was $15.9M, down sharply from $455.0M in H1 2025 which included a $416.3M gain on the SHPL divestment. The company reiterated full-year 2026 Oncology/Immunology revenue guidance of $330M-$450M and ended the period with $1.37B in cash. Key pipeline catalysts include expected SAFFRON and SANOVO Phase III readouts in H2 2026 and two sovleplenib NDAs under priority review in China.